Qualitative imaging features, such as frontal lobe tumor location, homogeneous signal intensity, sparse contrast enhancement within the tumor beds, and less intensive tumor infiltration are some of the imaging signatures that have been used to identify IDH-mutant gliomas with variable success [49,50,51]. The gene discussed is IDH2; the disease is central nervous system cancer.